We report on a patient with severe and fixed lichenoid drug-reaction. She did not respond to 2 months treatment with high-dose corticosteroids. Hence, Rituximab was given. One month later, her lesions improved and remained stable for 14 months of follow up. Keywords: fixed drug reaction, Prednesone, Rituximab
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined ...
We report our clinical experience with rituximab in the treatment of 2 patients with idiopathic cuta...
Certolizumab is a monoclonal antibody against tumour necrosis factor-alpha (TNF-α) commonly used in ...
We report a 73‐year‐old female with metastatic renal cell carcinoma who developed a widespread liche...
Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmog...
Introduction:With the advent of immunotherapy, a new subtype of side effects called IRAEs or immune ...
Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmog...
Immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1) are increasingly ...
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are generally safe and well-tol...
Adverse drug reactions can be predictable or unpredictable. Regardless, they must be communicated to...
Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent w...
This is a case report of an oral lichenoid drug reaction of the buccal sulci in a female diabetic pa...
Skin Involvement is seen nearly 76 per cent of Systemic lupus erythematosus (SLE) patients, but bull...
A 49-year-old man with recalcitrant mechanobullous epidermolysis bullosa acquisita (EBA) with signif...
Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogen...
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined ...
We report our clinical experience with rituximab in the treatment of 2 patients with idiopathic cuta...
Certolizumab is a monoclonal antibody against tumour necrosis factor-alpha (TNF-α) commonly used in ...
We report a 73‐year‐old female with metastatic renal cell carcinoma who developed a widespread liche...
Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmog...
Introduction:With the advent of immunotherapy, a new subtype of side effects called IRAEs or immune ...
Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmog...
Immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1) are increasingly ...
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are generally safe and well-tol...
Adverse drug reactions can be predictable or unpredictable. Regardless, they must be communicated to...
Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent w...
This is a case report of an oral lichenoid drug reaction of the buccal sulci in a female diabetic pa...
Skin Involvement is seen nearly 76 per cent of Systemic lupus erythematosus (SLE) patients, but bull...
A 49-year-old man with recalcitrant mechanobullous epidermolysis bullosa acquisita (EBA) with signif...
Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogen...
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined ...
We report our clinical experience with rituximab in the treatment of 2 patients with idiopathic cuta...
Certolizumab is a monoclonal antibody against tumour necrosis factor-alpha (TNF-α) commonly used in ...